Search
Nuvectis Pharma Inc
NVCTAdd to Watchlist
20.240USD
+0.010+0.05%
Close 11-13 16:00（ET）
659.42MMarket Cap
LossP/E TTM
Nuvectis Pharma Inc (NVCT) Stock Price Target & Forecast
Analyst Rating
Based on 6 analysts giving stock ratings to Nuvectis Pharma Inc in the past month.
Buy
0 Strong Buy
6 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
35.400USD+91.56%
NVCT Analyst Recommendation Trends
In the current month, NVCT has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NVCT average Analyst price target in the last month is 35.400.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
0
0
0
0
0
0
1
1
6
6
5
5
5
5
5
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
6
5
5
5
5
6
6
Financial Forecasting
Based on analysts' estimates, NVCT EPS is projected to reach -0.368 in FY2026Q4, following reported EPS of -1.020 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.31
-0.26
-0.24
-0.37
-0.30
Actual
-0.26
-0.30
-1.02
--
--
Surprise
+16.65%
-14.13%
-322.26%
--
--
FAQs
What is Nuvectis Pharma Inc's price target?
Analysts forecast that Nuvectis Pharma Inc's price target is USD 18.50, with the highest forecast at USD 25.00 and the lowest forecast at USD 10.00.
How have Nuvectis Pharma IncNVCT's recent earnings per share performed?
The market expectation was USD -1.02, while Nuvectis Pharma IncNVCT's earnings per share (EPS) for the previous quarter was USD -0.30. EPS for the next quarter is expected at USD -0.37.
What is the analyst rating for Nuvectis Pharma Inc?
Based on the ratings of Nuvectis Pharma Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.